CoChat

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease

Open access
Toth, Peter P., Dwyer, Jamie P., Cannon, Christopher P., Colhoun, Helen M., Rader, Daniel J., Upadhyay, Ashish, Louie, Michael J., Koren, Andrew, Letierce, Alexia, Mandel, Jonas, Banach, Maciej · 2018 · Kidney International
Cited by 112

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Individuals with chronic kidney disease are at increased risk of premature cardiovascular disease. Among them, many with elevated low-density lipoprotein cholesterol (LDL-C) are unable to achieve optimal LDL-C on statins and require additional lipid-lowering therapy. To study this, we compared the LDL-C-lowering efficacy and safety of alirocumab in individuals with hypercholesterolemia with impaired renal function, defined as eGFR 30–59 ml/min/1.73 m 2 , to those without impaired renal function eGFR ≥60 ml/min/1.73 m 2 . A total of 4629 hypercholesterolemic individuals without or with impaired renal function, pooled from eight phase 3 ODYSSEY trials (double-blind treatments of 24–104 weeks), were on alirocumab 150 mg or 75/150 mg every two weeks vs. placebo or ezetimibe. Overall, 10.1% had impaired renal function and over 99% were receiving statin treatment. Baseline LDL-C in alirocumab and control groups was comparable in subgroups analyzed. LDL-C reductions at week 24 ranged from 46.1 to 62.2% or 48.3 to 60.1% with alirocumab among individuals with or without impaired renal function, respectively. Similar reductions were observed for lipoprotein (a), non-high-density lipoprotein cholesterol, apolipoprotein B, and triglycerides. Safety data were similar in both treatment subgroups, regardless of the degree of CKD. Renal function did not change over time in response to alirocumab. This post hoc efficacy analysis is limited by evaluation of alirocumab treatment effects on renal and lipid parameters by serum biochemistry. Thus, alirocumab consistently lowered LDL-C regardless of impaired renal function, with safety comparable to control, among individuals with hypercholesterolemia who nearly all were on statin treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.kint.2017.12.011

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 112

Metadata

Authors
Toth, P. P., Dwyer, J. P., Cannon, C. P., Colhoun, H. M., Rader, D. J., Upadhyay, A., Louie, M. J., Koren, A., Letierce, A., Mandel, J., & Banach, M.
Venue
Kidney International
Publisher
Elsevier BV
Published
2018-06
Volume
93
Issue
6
Pages
1397-1408
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2792772811
Cited by
112
References
18
FWCI
13.90
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. https://app.cochat.ai/papers/10.1016/j.kint.2017.12.011
The paper
Toth, P. P., Dwyer, J. P., Cannon, C. P., Colhoun, H. M., Rader, D. J., Upadhyay, A., Louie, M. J., Koren, A., Letierce, A., Mandel, J., & Banach, M. (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International. https://doi.org/10.1016/j.kint.2017.12.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.